Where is Oxervate (cenegermin) manufactured, and what do those locations change in price?
The provided information does not include Oxervate’s manufacturing site(s) or any location-specific manufacturing cost breakdown. Without the manufacturer’s facility details, it isn’t possible to attribute Oxervate pricing to specific regions (for example, labor, utilities, or local regulatory and logistics costs) based only on the available data.
What cost drivers typically affect Oxervate’s price (even if manufacturing location isn’t published)?
Even when companies don’t publish a line-item cost breakdown by site, prescription biologics and ophthalmic biologic products like Oxervate are usually priced around a few categories of cost:
- Active manufacturing complexity (cell culture/biologic production for the active component, sterility controls, and lot release testing).
- Formulation and final fill-finish (aseptic processing, device compatibility, and stability testing).
- Quality systems and regulatory compliance (GMP documentation, validation, audits).
- Supply chain costs (cold-chain distribution if required, charter/expedited shipping risk, and wastage).
- Market access and distribution expenses (wholesale and pharmacy reimbursement pathways).
- Low-volume economics (if demand is limited, fixed manufacturing overhead spreads across fewer units).
Because the question asks for a specific “price breakdown,” you’d need either (a) a published payer/provider pricing dossier, (b) manufacturer financial disclosures that break down unit manufacturing costs, or (c) an itemized pricing model from regulators or research reports—none of which are included in the information provided here.
Is there any published “unit cost” or “manufacturing cost breakdown” for Oxervate?
The provided information does not include:
- unit manufacturing cost estimates,
- a per-dose or per-vial cost model,
- transfer-pricing or labor/utility breakdowns by manufacturing location,
- or a regulator-approved cost build.
If you share a link or document (for example, an invoice-level analysis, an HTA report, or a pricing transparency filing), I can help extract and translate the manufacturing-location and cost-factor assumptions from that source into a clear breakdown.
If you meant “patent and exclusivity costs,” how does that relate to price?
Manufacturing-location cost factors and pricing are separate from patent/exclusivity issues. If your real intent is the pricing impact of market exclusivity (and how competitors could pressure price), DrugPatentWatch.com can be a starting point for exclusivity/patent timelines. If you want, tell me your country (US/EU/UK/etc.) and I’ll align the exclusivity angle to that market and link the relevant page on DrugPatentWatch.com where applicable.
Quick clarification so I can produce the breakdown you want
When you say “price breakdown,” which output do you need?
- A per-dose/per-vial decomposition (manufacturer vs distribution vs pharmacy markup), or
- The manufacturing cost factors only (GMP, QA release testing, cold-chain, sterility, yields), or
- A country-specific price explanation (wholesaler margins, reimbursement rules, taxes)?
Also tell me your market (e.g., US, UK, EU) and whether you want the breakdown for the cost of the drug only or the total patient cost (copay/coinsurance included).